Influenza A virus vaccine H5N1 - Seqirus

Drug Profile

Influenza A virus vaccine H5N1 - Seqirus

Alternative Names: Aflunov; aH5N1c; FCC H5N1; Flu Cell Culture H5N1; Influenza A virus strain H5N1 vaccine - Seqirus; MF59™-adjuvanted-H5N1 subunit vaccine; Pre-pandemic H5N1 influenza vaccine - Seqirus; Pre-pandemic influenza vaccine - Seqirus

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator Novartis; Novartis Vaccines
  • Developer Seqirus
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 01 Jul 2016 Phase-III clinical trials in Influenza-A virus H5N1 subtype (In adults, In the elderly, Prevention) in USA (IM) (NCT02839330)
  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
  • 01 May 2015 Novartis completes a phase-III clinical trials in Influenza-A virus H5N1 subtype (in the Elderly, Prevention, in Adults) in Australia, Germany and Italy (IM) (NCT02107807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top